Ozge Koprulu

Dr. Ozge Koprulu

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Closed access
ÖNÖzlem Nalbantoğlu
Özlem Nalbantoğlu
GAGulcin Arslan
Gulcin Arslan
OKOzge Koprulu
Ozge Koprulu
FHFiliz Hazan
Filiz Hazan
SGSemra Gürsoy
Semra Gürsoy
BÖBehzat Özkan
Behzat Özkan
Idiopathic hypogonadotropic hypogonadism (IHH) is a rare disease caused by defects in the secretion of gonadotropin releasing hormone (GnRH) or the action of GnRH on the pituitary gonadotrophes. KISS1R is one of the genes which, when mutated, cause IHH and mutations of this gene are responsible for about 2-5% of patients with normosmic IHH (NIHH). In this report, we present three siblings with NIHH due to a compound heterozygous KISS1R mutation. Genetic studies were carried out in the 14 year old index case with IHH and three siblings, two of whom were prepubertal. Genomic DNA was extracted from peripheral leukocytes and KISS1R gene was sequenced by using standard polymerase chain reaction amplification procedures. In molecular analysis of the index case, a compound heterozygous mutation was determined in KISS1R gene c.969C>A (p.Y323X) (known pathogenic) and c.170T>C (p.L57P) (novel). Mutation c.170T>C (p.L57P) was inherited from the mother while c.969C>A (p.Y323X) was inherited from the father. The same genotype was also found in two of the three siblings. A compound heterozygous mutation of the KISS1 gene, including one novel mutation, was found to cause NIHH and also incomplete puberty in a non-consanguineous family.

7 March 2024 in Journal of Pediatric Endocrinology and Metabolism
Verified
Journal Article
Closed access
GAGözde Yazkan Akgül
Gözde Yazkan Akgül
OKOzge Koprulu
Ozge Koprulu
Objectives: The aim of our study is to examine the emotional, behavioral problems, and psychiatric symptoms of children diagnosed with Graves’ disease (GD), to assess their quality of life, and to compare with control group. Methods: The research was planned as a cross-sectional study and included 16 patients with GD (13 female and three male) and 29 healthy children for control group (19 female and 10 male). Sociodemographic form, Pediatric Quality of Life Inventory, Revised Child Anxiety and Depression Scale-Child Version (RCADS-CV), Strengths and Difficulties Questionnaire (SDQ), Turgay DSM-IV-Based Child and Adolescent Behavior Disorders Screening and Rating Scale (T-DSM-IV-S), and Affective Reactivity Index scale were applied to the children and their families. Results: Eighty one percent of GD group (GG) (n=13, mean age 15.1 ± 2.2) and 66 % of control group (CG) (n=19, 14.6 ± 2.2) were girls. No significant difference was found between GG and CG in terms of quality of life, anxiety, and depression scores. GG had higher scores in affective reactivity index, SDQ-P total score, and T-DSM-IV-S total scores (p values 0.039; 0.009; 0.023, respectively). While no significant difference was detected in the T-DSM-IV-S-inattention and hyperactivity scores, significantly higher scores were detected in oppositional defiance and conduct disorder scores (p values 0.172; 0.294; 0.019; 0.027, respectively). Conclusions: In children with GD, irritability, oppositional defiant, and conduct disorder symptoms have been detected. Children with these mental health symptoms experience behavioral and emotional difficulties in their daily lives. It is important to follow up children with GD for possible comorbid psychiatric disorders.

13 December 2022 in The Journal of Pediatric Research
Verified
Journal Article
Closed access
OKOzge Koprulu
Ozge Koprulu
SASezer Acar
Sezer Acar
KEKadri Murat Erdoğan
Kadri Murat Erdoğan
ÖNÖzlem Nalbantoğlu
Özlem Nalbantoğlu
TKTarık Kırkgöz
Tarık Kırkgöz
BÖBehzat Özkan
Behzat Özkan

1 December 2021 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
PDF file
ÖNÖzlem Nalbantoğlu
Özlem Nalbantoğlu
SASezer Acar
Sezer Acar
GAGulcin Arslan
Gulcin Arslan
OKOzge Koprulu
Ozge Koprulu
BÖBehzat Özkan
Behzat Özkan
The aim of this study was to evaluate the efficiency of buccal spray form of vitamin D compared to single oral dose (stoss therapy) and oral drops therapy in the treatment of vitamin D deficiency. Ninety healthy children and adolescents (3-18 years) with vitamin D deficiency [serum level of 25-hydroxyvitamin D (25OHD) < 12ng/ml] were randomized to receive vitamin D3 buccal spray (2000 U, n=30, group I) for 6-week period, oral drops (2000 U, n=30, group II) for 6-week period and a single oral dose (300 000 U) vitamin D 3 (n=30, group III). Serum calcium, phosphorus, ALP, PTH and 25OHD levels of the patients were measured at baseline and after the treatment (42th day). All 3 groups had a significant increase in serum 25 hydroxyvitamin D (25OHD) concentrations (p<0.001). Serum 25OHD concentration in group I was 22.1 (17.8-28.2) ng/ml as compared to baseline value of 8.0±0.41ng/ml, with the mean increase of 15.6±1.3 ng/ml. On the other hand, in group II and group III, the mean serum 25OHD concentrations were 24.4 (20.6-29.6) ng/ml and 40.3 (29.4-58.4) ng/ml as compared to baseline value of 7.9±0.45 ng/ml and 7.6±0.47 ng/ml, with the mean increase of 17.3±1.1ng/ml, 34.3±3.2 ng/ml, respectively. We conclude that vitamin D3 supplementation with buccal spray and oral drops is equally effective in terms of raising vitamin D concentrations in short-term treatment of vitamin D deficiency.

28 June 2022 in SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital
Verified
Journal Article
Open access
OKOzge Koprulu
Ozge Koprulu
BOBehzat Ozkan
Behzat Ozkan
SASezer Acar
Sezer Acar
ONOzlem Nalbantoglu
Ozlem Nalbantoglu
BOBeyhan Ozkaya
Beyhan Ozkaya
SGSemra Gursoy
Semra Gursoy
The Medical Bulletin of Sisli Etfal Hospital

3 June 2025 in Molecular Syndromology
Verified
Journal Article
Closed access
GTGulin Tabanli
Gulin Tabanli
FHFiliz Hazan
Filiz Hazan
GOGulsen Ozer
Gulsen Ozer
OKOzge Koprulu
Ozge Koprulu
ONOzlem Nalbantoglu
Ozlem Nalbantoglu
BOBehzat Ozkan
Behzat Ozkan
Introduction: Opsismodysplasia (OPS) is a rare skeletal dysplasia characterized by delayed bone maturation, distinctive skeletal deformities, and severe growth impairment. Mutations in the INPPL1 gene, particularly homozygous variants, are the primary genetic cause of this condition. While bisphosphonate therapy has shown efficacy in OPS cases with hypophosphatemic rickets, its role in cases without this complication remains unclear. Case Presentation: A 2-year-and-2-month-old girl with OPS was treated with intravenous pamidronate (0.5 mg/kg/3 months). Initial evaluations showed severe short stature and low bone mineral density (DEXA SDS: −3.16). After three courses of treatment, the patient achieved independent walking, and her DEXA SDS improved to −2.5 over 1 year. Discussion: Pamidronate is effective in treating OPS even in the absence of hypophosphatemic rickets, showing potential as a therapeutic option for this rare condition.